FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281779830> ?p ?o ?g. }

• W4281779830 endingPage "e055742" @default.
• W4281779830 startingPage "e055742" @default.
• W4281779830 abstract "Neoantigens derived from tumour somatic mutations are recognised as ideal vaccine targets. Tumour neoantigens have been studied in a wide range of tumours. Most of research on neoantigens has focused just on a unique tumour and a single mutated gene. Currently, a few studies have reported using a mixture of neoantigen peptides derived from multiple genetic mutation sites in the treatment of genomic unstable advanced solid malignancies. The trial aims to evaluate the safety and efficacy of individualised tumour neoantigen peptide mixtures in the treatment of genomic unstable advanced solid malignant tumours.This is a prospective, non-randomised, open, single-centre, single-arm, phase I trial. Patients with genomic unstable advanced solid malignancies are eligible for study participations. 20 patients will be included in the trial. Through the whole exome and transcriptome sequencing analysis of the fresh blood and tumour tissues of the enrolled patients, the 20 25-33aa antigen peptides with the highest mutation scores of the patients will be screened out, and the corresponding new antigen peptides will be synthesised and prepared. Patients will be treated with their own individualised neoantigen polypeptide combined with a polypeptide adjuvant (human granulocyte-macrophage colony-stimulating factor). The primary endpoint is safety indicators, including general and specific adverse events which will be monitored continuously. Secondary endpoints are progression-free survival, objective response rate, objective duration of remission, 1-year survival rate and overall survival.This study has received approval from the Ethics Committee of Chongqing University Cancer Hospital on 21 November 2019 (207/2019). The findings of this trial will be disseminated through national and international presentations and peer-reviewed publications.ChiCTR1900025364." @default.
• W4281779830 created "2022-06-13" @default.
• W4281779830 creator A5002345896 @default.
• W4281779830 creator A5021128375 @default.
• W4281779830 creator A5034027148 @default.
• W4281779830 creator A5043811778 @default.
• W4281779830 creator A5049024305 @default.
• W4281779830 creator A5060630635 @default.
• W4281779830 creator A5065418722 @default.
• W4281779830 date "2022-06-01" @default.
• W4281779830 modified "2023-09-23" @default.
• W4281779830 title "Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial" @default.
• W4281779830 cites W1912693401 @default.
• W4281779830 cites W2007026865 @default.
• W4281779830 cites W2009834549 @default.
• W4281779830 cites W2011458181 @default.
• W4281779830 cites W2020259979 @default.
• W4281779830 cites W2021472146 @default.
• W4281779830 cites W2152061559 @default.
• W4281779830 cites W2167571044 @default.
• W4281779830 cites W2187527489 @default.
• W4281779830 cites W2198252241 @default.
• W4281779830 cites W2403289604 @default.
• W4281779830 cites W2587111948 @default.
• W4281779830 cites W2588457489 @default.
• W4281779830 cites W2590497374 @default.
• W4281779830 cites W2712978371 @default.
• W4281779830 cites W2728365508 @default.
• W4281779830 cites W2791512052 @default.
• W4281779830 cites W2799360291 @default.
• W4281779830 cites W2889651900 @default.
• W4281779830 cites W2891436740 @default.
• W4281779830 cites W2898544952 @default.
• W4281779830 cites W2904803926 @default.
• W4281779830 cites W2957226098 @default.
• W4281779830 cites W2978289879 @default.
• W4281779830 cites W2982049472 @default.
• W4281779830 cites W2987417623 @default.
• W4281779830 cites W3004611567 @default.
• W4281779830 cites W3011964824 @default.
• W4281779830 cites W3014583893 @default.
• W4281779830 cites W3019306048 @default.
• W4281779830 cites W3027458630 @default.
• W4281779830 cites W3122472315 @default.
• W4281779830 cites W3124720941 @default.
• W4281779830 cites W3137406939 @default.
• W4281779830 cites W3155586063 @default.
• W4281779830 cites W3185970817 @default.
• W4281779830 cites W3194355129 @default.
• W4281779830 cites W3210670887 @default.
• W4281779830 cites W4200578065 @default.
• W4281779830 cites W4213133353 @default.
• W4281779830 doi "https://doi.org/10.1136/bmjopen-2021-055742" @default.
• W4281779830 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35688598" @default.
• W4281779830 hasPublicationYear "2022" @default.
• W4281779830 type Work @default.
• W4281779830 citedByCount "0" @default.
• W4281779830 crossrefType "journal-article" @default.
• W4281779830 hasAuthorship W4281779830A5002345896 @default.
• W4281779830 hasAuthorship W4281779830A5021128375 @default.
• W4281779830 hasAuthorship W4281779830A5034027148 @default.
• W4281779830 hasAuthorship W4281779830A5043811778 @default.
• W4281779830 hasAuthorship W4281779830A5049024305 @default.
• W4281779830 hasAuthorship W4281779830A5060630635 @default.
• W4281779830 hasAuthorship W4281779830A5065418722 @default.
• W4281779830 hasBestOaLocation W42817798301 @default.
• W4281779830 hasConcept C104317684 @default.
• W4281779830 hasConcept C10590036 @default.
• W4281779830 hasConcept C121608353 @default.
• W4281779830 hasConcept C126322002 @default.
• W4281779830 hasConcept C143998085 @default.
• W4281779830 hasConcept C147483822 @default.
• W4281779830 hasConcept C16671776 @default.
• W4281779830 hasConcept C185592680 @default.
• W4281779830 hasConcept C197934379 @default.
• W4281779830 hasConcept C203014093 @default.
• W4281779830 hasConcept C203092338 @default.
• W4281779830 hasConcept C2777701055 @default.
• W4281779830 hasConcept C2777863537 @default.
• W4281779830 hasConcept C501734568 @default.
• W4281779830 hasConcept C535046627 @default.
• W4281779830 hasConcept C55493867 @default.
• W4281779830 hasConcept C71924100 @default.
• W4281779830 hasConceptScore W4281779830C104317684 @default.
• W4281779830 hasConceptScore W4281779830C10590036 @default.
• W4281779830 hasConceptScore W4281779830C121608353 @default.
• W4281779830 hasConceptScore W4281779830C126322002 @default.
• W4281779830 hasConceptScore W4281779830C143998085 @default.
• W4281779830 hasConceptScore W4281779830C147483822 @default.
• W4281779830 hasConceptScore W4281779830C16671776 @default.
• W4281779830 hasConceptScore W4281779830C185592680 @default.
• W4281779830 hasConceptScore W4281779830C197934379 @default.
• W4281779830 hasConceptScore W4281779830C203014093 @default.
• W4281779830 hasConceptScore W4281779830C203092338 @default.
• W4281779830 hasConceptScore W4281779830C2777701055 @default.
• W4281779830 hasConceptScore W4281779830C2777863537 @default.
• W4281779830 hasConceptScore W4281779830C501734568 @default.
• W4281779830 hasConceptScore W4281779830C535046627 @default.

• next